Suppr超能文献

病原体驱动的癌症和新兴的免疫治疗策略。

Pathogen-driven cancers and emerging immune therapeutic strategies.

机构信息

Authors' Affiliation: Department of Dermatology/Medicine, University of Washington, Seattle, Washington.

出版信息

Cancer Immunol Res. 2014 Jan;2(1):9-14. doi: 10.1158/2326-6066.CIR-13-0179.

Abstract

Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention of infection and antimicrobial treatments have helped in reducing infection rates and the incidence of associated malignancies, therapies for these cancers remain limited. The importance of immune control over malignant progression is highlighted by the fact that many cancers, particularly those induced by pathogens, occur more frequently among immunosuppressed patients as compared with healthy individuals. Therefore, therapeutic strategies that can elicit a robust immune response and restore tumor detection may be a beneficial approach for treating these cancers. In addition, the study of immune escape mechanisms used by pathogens and their associated cancers may provide insight into the mechanisms of malignant transformation and improved therapies for cancer more generally.

摘要

在全球范围内,约有 20%的癌症病例与感染因子有关。已知有 11 种病原体(7 种病毒、3 种寄生虫和 1 种细菌)通过表达其蛋白产物直接或通过慢性炎症间接促进肿瘤发生。尽管预防感染和抗菌治疗有助于降低感染率和相关恶性肿瘤的发病率,但这些癌症的治疗方法仍然有限。免疫对恶性进展的控制作用非常重要,因为许多癌症,特别是由病原体引起的癌症,在免疫抑制患者中的发病率高于健康人群。因此,能够引发强烈免疫反应并恢复肿瘤检测的治疗策略可能是治疗这些癌症的一种有益方法。此外,研究病原体及其相关癌症所使用的免疫逃逸机制,可能有助于了解恶性转化的机制,并为癌症的治疗提供更广泛的改进方法。

相似文献

1
Pathogen-driven cancers and emerging immune therapeutic strategies.
Cancer Immunol Res. 2014 Jan;2(1):9-14. doi: 10.1158/2326-6066.CIR-13-0179.
2
Viruses and human cancers: a long road of discovery of molecular paradigms.
Clin Microbiol Rev. 2014 Jul;27(3):463-81. doi: 10.1128/CMR.00124-13.
3
An epi(c)genetic war: Pathogens, cancer and human genome.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):333-345. doi: 10.1016/j.bbcan.2018.04.003. Epub 2018 Apr 13.
4
The human immune system's response to carcinogenic and other infectious agents transmitted by mosquito vectors.
Parasitol Res. 2017 Jan;116(1):1-9. doi: 10.1007/s00436-016-5272-2. Epub 2016 Oct 27.
5
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View.
Trends Cancer. 2020 Mar;6(3):192-204. doi: 10.1016/j.trecan.2020.01.004. Epub 2020 Feb 7.
6
Immunotherapy against cancer-related viruses.
Cell Res. 2017 Jan;27(1):59-73. doi: 10.1038/cr.2016.153. Epub 2016 Dec 23.
7
Immune-based therapeutic approaches to virus-associated cancers.
Curr Opin Virol. 2018 Oct;32:24-29. doi: 10.1016/j.coviro.2018.08.010. Epub 2018 Sep 18.
8
Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.
Immunol Cell Biol. 2017 Apr;95(4):364-371. doi: 10.1038/icb.2016.127. Epub 2017 Jan 10.
9
Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.
J Immunother. 2012 May;35(4):299-308. doi: 10.1097/CJI.0b013e3182518e83.
10
Infectious agents and cancer: criteria for a causal relation.
Semin Cancer Biol. 2004 Dec;14(6):453-71. doi: 10.1016/j.semcancer.2004.06.009.

引用本文的文献

1
Oncogenic viruses rewire the epigenome in human cancer.
Front Cell Infect Microbiol. 2025 Jun 10;15:1617198. doi: 10.3389/fcimb.2025.1617198. eCollection 2025.
2
Advances in understanding the mechanisms of the human papillomavirus oncoproteins.
Biochem Soc Trans. 2025 Jun 30;53(3):565-577. doi: 10.1042/BST20253041.
3
Viral oncogenesis in cancer: from mechanisms to therapeutics.
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
5
Anticancer properties and metabolomic profiling of Shorea roxburghii extracts toward gastrointestinal cancer cell lines.
BMC Complement Med Ther. 2024 Apr 30;24(1):178. doi: 10.1186/s12906-024-04479-1.
7
Editorial: Host-microbiota and cancer.
Front Oncol. 2023 Mar 17;13:1154586. doi: 10.3389/fonc.2023.1154586. eCollection 2023.
8
Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma.
Front Genet. 2023 Jan 4;13:1065644. doi: 10.3389/fgene.2022.1065644. eCollection 2022.

本文引用的文献

2
Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?
Clin Cancer Res. 2013 Sep 1;19(17):4550-2. doi: 10.1158/1078-0432.CCR-13-1367. Epub 2013 Aug 6.
3
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10.
5
The basic principles of chimeric antigen receptor design.
Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2.
8
Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage.
J Invest Dermatol. 2013 Mar;133(3):642-646. doi: 10.1038/jid.2012.388. Epub 2012 Nov 29.
9
Using antimicrobial adjuvant therapy in cancer treatment: a review.
Infect Agent Cancer. 2012 Nov 20;7(1):33. doi: 10.1186/1750-9378-7-33.
10
Epidemiological Aspects and World Distribution of HTLV-1 Infection.
Front Microbiol. 2012 Nov 15;3:388. doi: 10.3389/fmicb.2012.00388. eCollection 2012.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验